EyePoint Pharmaceuticals, Inc. (EYPT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
EYPT currently has 83.8M outstanding shares. with significant dilution risk as 115M authorized shares could dilute existing holders by 137.0%. The company has significantly diluted shareholders by 51.87% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 83.8M shares outstanding |
84M | 110M |
| Nov 06, 2025 |
10-Q filing | 82.8M shares outstanding |
83M | 120M |
| Aug 07, 2025 |
10-Q filing | 68.9M shares outstanding |
69M | 130M |
| May 08, 2025 |
10-Q filing | 69.8M shares outstanding |
70M | 130M |
| Mar 06, 2025 |
10-K filing | 68.7M shares outstanding |
69M | 130M |
| Nov 07, 2024 |
10-Q filing | 68.3M shares outstanding |
68M | 130M |
| Aug 08, 2024 |
10-Q filing | 53.2M shares outstanding |
53M | 150M |
| Aug 08, 2024 |
S-3 filing: The company is filing an S-3 to offer common stock, preferred stock, warrants, debt securities, and units consisting of a combination of the foregoing securities up to an aggregate initial offering price of $400,000,000. |
53M | 150M |
| May 09, 2024 |
10-Q filing | 52.1M shares outstanding |
52M | 150M |
| Mar 08, 2024 |
10-K filing | 49.8M shares outstanding |
50M | 150M |
| Nov 03, 2023 |
10-Q filing | 38.3M shares outstanding |
38M | 160M |
| Oct 20, 2023 |
S-3 filing: The filing is an S-3 shelf registration for common stock, preferred stock, warrants, debt securities, and units with a total offering price not exceeding $350,000,000. |
38M | 160M |
| Aug 04, 2023 |
10-Q filing | 37.6M shares outstanding |
38M | 110M |
| May 04, 2023 |
10-Q filing | 37.5M shares outstanding |
37M | 110M |
| Mar 10, 2023 |
10-K filing | 37.3M shares outstanding |
37M | 110M |
| Nov 04, 2022 |
10-Q filing | 37.3M shares outstanding |
37M | 110M |
| Aug 05, 2022 |
10-Q filing | 37.3M shares outstanding |
37M | 110M |
| May 06, 2022 |
10-Q filing | 34.0M shares outstanding |
34M | 120M |
| Mar 14, 2022 |
10-K filing | 34.0M shares outstanding |
34M | 120M |
| Nov 05, 2021 |
10-Q filing | 28.8M shares outstanding |
29M | 120M |
| Aug 06, 2021 |
S-3 filing: This is an S-3 filing for a shelf offering of common stock, preferred stock, warrants to purchase shares of common stock, preferred stock and/or debt securities, debt securities consisting of debentures, notes or other evidences of indebtedness, units consisting of a combination of the foregoing securities; or any combination of these securities with a total proposed amount of $350,000,000. An additional ATM offering of common stock through Cantor Fitzgerald with an aggregate offering price of up to $50,000,000 is described. |
29M | 120M |
| Aug 06, 2021 |
10-Q filing | 28.8M shares outstanding |
29M | 120M |
| May 05, 2021 |
10-Q filing | 28.7M shares outstanding |
29M | 120M |
| May 05, 2021 |
S-3/A filing: This S-3/A filing relates to the resale of 3,010,722 shares of common stock by a selling stockholder. |
29M | 120M |
| Mar 12, 2021 |
10-K filing | 28.7M shares outstanding |
29M | 120M |
| Feb 12, 2021 |
S-3 filing: This prospectus relates to the resale of up to 3,010,722 shares of common stock by the selling stockholder. |
140M | 3M |
| Jan 15, 2021 |
S-3 filing: The filing is an S-3 form indicating Eyepoint Pharmaceuticals may offer common stock, preferred stock, warrants, debt securities, or units up to an aggregate amount of $250,000,000. |
140M | 0 |
| Jan 04, 2021 |
8-K filing: Ocumension Therapeutics purchased 3,010,722 shares of the company's common stock at $5.2163 per share for gross proceeds of approximately $15.7 million. ($15.7M proceeds) |
140M | 0 |
| Nov 06, 2020 |
10-Q filing | 143.5M shares outstanding |
140M | 0 |
| Aug 05, 2020 |
10-Q filing | 125.2M shares outstanding |
130M | 0 |
| May 08, 2020 |
10-Q filing | 124.7M shares outstanding |
120M | 0 |
| Mar 16, 2020 |
10-K filing | 124.7M shares outstanding |
120M | 0 |